1. Rhythm Pharmaceuticals. Rhythm Pharmaceuticals announces FDA approval of IMCIVREETM (setmelanotide) as first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency [media release]. 27 Nov 2020. http://www.rhythmtx.com/.
2. Ryan DH. Setmelanotide: what does it mean for clinical care of patients with obesity? Lancet Diabetes Endocrinol. 2020;8(12):933–5.
3. Kuhnen P, Clement K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–6.
4. Rhythm Pharmaceuticals. Setmelanotide (IMCIVREE™): US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf. Accessed 2 Dec 2020.
5. US Food and Drug Administration. FDA approves first treatment for weight management for people with certain rare genetic conditions [media release]. 27 Nov 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions.